Kiniksa Pharmaceuticals International, PLC Form 4 insider transactions

John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals, receives performance share units and options tied to the progress of KPL-387.

Chief Commercial Officer Ross Moat exercised stock options and sold shares of Kiniksa Pharmaceuticals International, plc, according to a recent SEC Form 4 filing.

Mark Ragosa, CFO of Kiniksa Pharmaceuticals, reports exercising stock options and selling Class A Ordinary Shares under a pre-arranged 10b5-1 trading plan.

Mark Ragosa, CFO of Kiniksa Pharmaceuticals International, plc, reports the vesting and subsequent disposal of Class A Ordinary Shares to cover tax obligations.

Chief Commercial Officer Ross Moat sold 18,259 shares of Kiniksa Pharmaceuticals International, plc under a pre-arranged 10b5-1 trading plan.

Chief Operating Officer Eben Tessari exercised stock options and sold Kiniksa Pharmaceuticals shares under a pre-arranged 10b5-1 trading plan.

Eben Tessari, Chief Operating Officer of Kiniksa Pharmaceuticals International, plc, reports the acquisition and disposal of Class A Ordinary Shares on April 7, 2025.

Chief Financial Officer Mark Ragosa of Kiniksa Pharmaceuticals International, plc, reports the acquisition and disposal of Class A Ordinary Shares and Restricted Share Units.

Sanj K Patel, Chairman and CEO of Kiniksa Pharmaceuticals International, plc, reports the vesting and disposal of restricted share units and related tax withholding.

Chief Medical Officer John F. Paolini exercised stock options and sold shares of Kiniksa Pharmaceuticals International, plc on April 7, 2025.

Ross Moat, Chief Commercial Officer of Kiniksa Pharmaceuticals International, plc, reports the acquisition and disposal of Class A Ordinary Shares and Restricted Share Units on April 7, 2025.

Michael Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals International, plc, reports the acquisition and disposal of Class A Ordinary Shares and Restricted Share Units.

Ross Moat, Chief Commercial Officer of Kiniksa Pharmaceuticals International, plc, reports acquisition and disposal of Class A Ordinary Shares and derivative securities.

Chief Medical Officer John F. Paolini reports acquisition and disposal of Kiniksa Pharmaceuticals International, plc shares, including options and restricted share units.

Mark Ragosa, CFO of Kiniksa Pharmaceuticals International, plc, reports acquisition and disposal of Class A Ordinary Shares and derivative securities.

Eben Tessari, Chief Operating Officer of Kiniksa Pharmaceuticals International, plc, reports acquisition and disposal of Class A Ordinary Shares and derivative securities.

Sanj K. Patel, Chairman and CEO of Kiniksa Pharmaceuticals International, plc, reports acquisition and disposal of Class A Ordinary Shares and derivative securities.

Michael R. Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals International, plc, reports acquisition and disposal of Class A Ordinary Shares and Restricted Share Units.

Mark Ragosa, CFO of Kiniksa Pharmaceuticals International, plc, sold 15,944 Class A Ordinary Shares on March 20, 2025, under a pre-arranged 10b5-1 trading plan.

Mark Ragosa, CFO of Kiniksa Pharmaceuticals, reports multiple transactions involving Class A Ordinary Shares, including acquisitions and disposals, under a pre-arranged 10b5-1 trading plan.

Ross Moat, Chief Commercial Officer of Kiniksa Pharmaceuticals International, plc, reports acquisition and disposal of Class A Ordinary Shares.

Michael Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals, reports acquisition and disposal of Class A Ordinary Shares and Restricted Share Units.

Eben Tessari, Chief Operating Officer of Kiniksa Pharmaceuticals International, plc, reports the disposition of shares to cover tax obligations related to vested restricted share units.

Sanj K. Patel, Chairman & CEO of Kiniksa Pharmaceuticals International, plc, reported the disposal of Class A Ordinary Shares to cover tax obligations related to vested Restricted Share Units (RSUs).

John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals International, plc, reports the vesting of restricted share units and subsequent share disposals to cover tax obligations.

Michael Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals International, plc, reports the acquisition and disposal of Class A Ordinary Shares on March 12, 2025, pursuant to a pre-arranged 10b5-1 trading plan.

Mark Ragosa, CFO of Kiniksa Pharmaceuticals International, plc, sold 36,372 Class A Ordinary Shares at $11.97 and 36,372 Class A Ordinary Shares at $22.25 on March 12, 2025, according to a Form 4 filing.

Chief Operating Officer Tessari Eben reports the exercise of options and sale of Class A Ordinary Shares of Kiniksa Pharmaceuticals International, plc on March 10, 2025, pursuant to a pre-arranged 10b5-1 trading plan.

Eben Tessari, Chief Operating Officer of Kiniksa Pharmaceuticals International, plc, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Eben Tessari, Chief Operating Officer of Kiniksa Pharmaceuticals International, plc, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.